Clopidogrel Bisulfate
Product Images NDC 67296-1869

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 67296-1869). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 01)

Chemical structure of Clopidogrel Bisulfate showing the molecular arrangement including a piperidine ring, thiophene ring, ester group, and chloride-substituted phenyl ring with a sulfate adduct.*

FDA Label Image

Fig 1 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 02)

A chart depicting the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of clopidogrel, showing mean values and 90% confidence intervals for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The x-axis represents change relative to clopidogrel tablets administered alone, ranging from 0.4 to 1.4.*

FDA Label Image

Fig 2 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 03)

A line graph illustrating cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares outcomes between two groups: placebo plus aspirin and clopidogrel bisulfate plus aspirin, showing lower event rates for the clopidogrel bisulfate group. The graph includes a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Fig 3 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 04)

A forest plot chart showing subgroup analysis of Clopidogrel versus placebo in various populations by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. It presents hazard ratios with 95% confidence intervals for each subgroup, comparing incidence rates summarized with diamond markers along a horizontal axis ranging from 0.3 to 1.4, indicating treatment effect favoring Clopidogrel or placebo.*

FDA Label Image

Fig3-a (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 05)

A data table presenting subgroup analysis comparing Clopidogrel versus placebo outcomes measured by hazard ratios with 95% confidence intervals. Subgroups include Heparin/LMWH, Aspirin dosage levels, GPIIb/IIIa antagonist, Beta-Blocker, and Ace Inhibitor use, with corresponding patient numbers and event percentages in each group. The table includes a forest plot visualization of hazard ratios favoring Clopidogrel or placebo.*

FDA Label Image

Fig 4 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 06)

A line graph showing the percentage of deaths before first discharge over days since randomization (up to 28 days) comparing placebo and Clopidogrel groups. The placebo group shows 1845 deaths (8.1%), while the Clopidogrel group has 1726 deaths (7.5%) with a 7% proportional risk reduction (p = 0.03). A note indicates all patients received aspirin.*

FDA Label Image

Fig 5 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 07)

A graph showing the cumulative percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization, comparing Clopidogrel and Placebo groups. The Placebo group shows a 10.1% event rate, while the Clopidogrel group has a 9.2% event rate, indicating a 9% proportional risk reduction (p = 0.002). All treated patients received aspirin.*

FDA Label Image

Fig 6 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 08)

A forest plot chart comparing Clopidogrel and placebo across subgroups, including gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart displays odds ratios with 99% confidence intervals indicating relative effects favoring Clopidogrel or placebo, along with subgroup sample sizes and event percentages.*

FDA Label Image

Fig 8 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 09)

A line graph comparing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel bisulfate and Aspirin, showing slightly lower rates for Clopidogrel bisulfate throughout the period, with a p-value of 0.045 indicated.*

FDA Label Image

Fig 5 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 10)

A forest plot chart showing the hazard ratio (with 95% confidence intervals) comparing Clopidogrel and Aspirin across different qualifying conditions: Stroke, MI (Myocardial Infarction), PAD (Peripheral Artery Disease), and Overall. The chart includes numerical counts and percentages of events for both Clopidogrel and Aspirin groups for each condition.*

FDA Label Image

Fig6 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 11)

FDA Label Image

1 (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 12)

FDA Label Image

Label (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 13)

Clopidogrel Tablets, USP 75 mg in a container label showing 30 tablets with NDC 13668-141-30. The label includes storage instructions, dosage information, and notes that the tablets are manufactured by Torrent Pharmaceuticals Ltd and Torrent Pharma Inc. The label specifies the product is for Rx only and includes pharmacist dispensing instructions.*

FDA Label Image

75mg- Dahej (Cb88b6f1 F604 4bb0 Ae74 2d98ec6193bd 14)

Label for Clopidogrel Tablets USP 75 mg, containing 30 tablets. The label includes storage instructions, dosage note, and manufacturer details (Torrent Pharmaceuticals Ltd., India). It shows NDC 13668-141-30 with a barcode and prescribing information advisory. The label is for prescription use (Rx only).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.